分组1 - Quest Diagnostics reported quarterly earnings of $2.30 per share, exceeding the Zacks Consensus Estimate of $2.26 per share, and showing an increase from $2.22 per share a year ago, representing an earnings surprise of 1.77% [1] - The company generated revenues of $2.49 billion for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 3.36%, and up from $2.3 billion in the same quarter last year [1] - Over the last four quarters, Quest Diagnostics has consistently surpassed consensus EPS and revenue estimates [1] 分组2 - The stock has added approximately 6.9% since the beginning of the year, underperforming compared to the S&P 500's gain of 22.7% [2] - The current consensus EPS estimate for the upcoming quarter is $2.22 on revenues of $2.46 billion, and for the current fiscal year, it is $8.89 on revenues of $9.63 billion [4] - The Medical - Outpatient and Home Healthcare industry, to which Quest Diagnostics belongs, is currently ranked in the top 10% of over 250 Zacks industries, indicating a favorable outlook for the sector [5]

Revenue and Earnings Performance - Third quarter revenues of $2.49 billion, up 8.5% from 2023[1] - Third quarter reported diluted EPS of $1.99, up 1.5% from 2023; adjusted diluted EPS of $2.30, up 3.6% from 2023[1] - Full year 2024 revenues expected to be between $9.80 billion and $9.85 billion; reported diluted EPS expected to be between $7.60 and $7.70; adjusted diluted EPS expected to be between $8.85 and $8.95[1] - Diagnostic Information Services revenues of $2.427 billion, up 9.0% from 2023[2] - Revenue per requisition increased by 3.3% and requisition volume increased by 5.5% in the third quarter[2] - Adjusted operating income increased by 1.3% to $385 million in the third quarter[2] - Adjusted net income attributable to Quest Diagnostics increased by 3.1% to $262 million in the third quarter[2] - Net income attributable to Quest Diagnostics was $649 million for the nine months ended September 2024, slightly down from $662 million in 2023[14] - Diluted earnings per share (EPS) for the nine months ended September 2024 was $5.74, compared to $5.79 in 2023[14] - Adjusted operating income for the nine months ended September 2024 was $1,132 million, representing 15.6% of net revenues[17] - Adjusted diluted EPS for the nine months ended September 2024 was $6.70, up from $5.79 in 2023[17] - Operating income for the nine months ended September 30, 2023, was $995 million, representing 14.3% of net revenues[19] - Adjusted operating income for the same period was $1,119 million, or 16.1% of net revenues[19] Cash Flow and Financial Position - Cash provided by operations increased by 72.5% to $356 million in the third quarter[2] - Net cash provided by operating activities was $870 million for the nine months ended September 2024, compared to $745 million in the same period in 2023[13] - Cash and cash equivalents increased to $764 million in September 2024 from $686 million in December 2023[11] - Long-term debt rose to $5,648 million in September 2024 from $4,410 million in December 2023[11] - Business acquisitions, net of cash acquired, totaled $1,781 million for the nine months ended September 2024[13] - Capital expenditures were $302 million for the nine months ended September 2024, down from $336 million in 2023[13] Acquisitions and Growth - The company has completed eight acquisitions by year-end, contributing to revenue growth and profitability[2] - Total assets increased to $16,095 million in September 2024 from $14,022 million in December 2023, reflecting growth in goodwill and intangible assets[11] - Pre-tax losses of $13 million are expected in 2024 due to the increase in fair value of contingent consideration from previous acquisitions[24] - Pre-tax losses of $11 million are anticipated in 2024 from changes in the carrying value of strategic investments[24] - A non-recurring pre-tax gain of $8 million is expected in 2024 from a foreign exchange forward contract related to an acquisition[25] Restructuring and Integration - Restructuring and integration charges for the nine months ended September 30, 2023, totaled $32 million, with a pre-tax impact of $45 million[21] - Estimated pre-tax restructuring and integration charges for 2024 are $50 million, primarily related to workforce reductions[24] - Estimated pre-tax amortization expenses for 2024 are $129 million[24] - Amortization expense for the nine months ended September 30, 2023, was $81 million[19] External Factors Impact - The company expects Hurricane Milton to negatively impact net revenues by approximately $15 million and EPS by approximately 8 cents in the fourth quarter[3]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Quest Diagnostics, driven by higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Quest Diagnostics is expected to report quarterly earnings of $2.26 per share, reflecting a +1.8% change year-over-year, with revenues projected at $2.4 billion, up 4.6% from the previous year [3]. - The earnings report is scheduled for October 22, 2024, and could influence stock movement based on whether results exceed or fall short of expectations [2]. Estimate Revisions - The consensus EPS estimate has been revised 0.35% higher in the last 30 days, indicating a reassessment by analysts [4]. - A negative Earnings ESP of -1.34% suggests analysts have recently become bearish on the company's earnings prospects, despite a Zacks Rank of 2 [10]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict earnings deviation from consensus estimates, with positive readings being more reliable [6][7]. - Stocks with a positive Earnings ESP and a strong Zacks Rank have historically shown a nearly 70% success rate in beating earnings expectations [8]. Historical Performance - Quest Diagnostics has beaten consensus EPS estimates in the last four quarters, with a recent surprise of +1.73% in the last reported quarter [11][12]. - Despite a history of earnings beats, other factors can influence stock performance, making it essential to consider broader market conditions [13]. Investment Considerations - While Quest Diagnostics may not appear to be a compelling earnings-beat candidate, investors should monitor additional factors before making investment decisions [15].

First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium Self-collection option available at no extra charge at any of Quest's 2,000 patient service centers with a physician's order or through Quest's consumer-initiated test platform at questhealth.com SECAUCUS, N.J., Oct. 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnosti ...

The medical laboratory testing industry is growing at a 1-3% compound annual growth rate and is dominated by two publicly traded companies. Quest Diagnostics (NYSE: DGX ) is the stronger of the two companies and is actively I am an individual investor with over two decades of investing experience. I am passionate about finding great value buys and pursuing dividend growth investing, from domestic to international companies. I invest in businesses, not stocks!I cover all aspects of value investing, dividend ...

Quest Diagnostics (DGX) is set to release its third-quarter 2024 results on Oct. 22, before the opening bell. The medical diagnostic testing provider posted adjusted earnings per share (EPS) of $2.35 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 1.73%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 3.31%. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. DGX's Q3 Estimates For the third quarter of ...

Core Insights - Quest Diagnostics has completed the acquisition of select laboratory assets from OhioHealth to enhance access to cost-effective and innovative laboratory services in Ohio [1][2] Group 1: Transaction Details - The financial terms of the acquisition have not been disclosed [1] - The primary goal of the transaction is to broaden access to Quest's extensive test menu and patient service network, which will lower out-of-pocket costs for patients [2] Group 2: Operational Changes - Quest's full-service laboratory in Pittsburgh will take over most outreach testing previously conducted by OhioHealth [3] - OhioHealth will maintain ownership and operation of its hospital labs for inpatient and outpatient care, as well as anatomic pathology and oncology services [3] Group 3: Company Profiles - Quest Diagnostics is a leader in diagnostic information services, serving one in three adult Americans and half of the physicians and hospitals in the U.S. [6] - OhioHealth is a not-for-profit healthcare system with a network of 15 hospitals and over 200 ambulatory sites, serving a 50-county area in Ohio [5]

Quest Diagnostics Inc. (DGX) continues the strong momentum in its expanding portfolio of Advanced Services, which is poised to help it grow in the upcoming quarters. The company strategically deploys AI and automation to improve its operational quality and efficiency, while Invigorate aims to reach its annual target. Its base business volume remains robust, which is highly encouraging. However, the mounting debt burden on its balance sheet and industry headwinds could pose challenges for Quest Diagnostics' ...

SECAUCUS, N.J., Sept. 25, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report third quarter 2024 financial results on Tuesday, October 22, 2024, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode ...

Core Viewpoint - Quest Diagnostics (DGX) is experiencing growth driven by strong customer relationships, new client acquisitions, broad health plan access, and advanced diagnostics offerings, currently holding a Zacks Rank 2 (Buy) [1] Factors Driving DGX Stock - The company has seen robust volume growth in its core business, with base clinical volumes increasing by 3.2% in Q2 2024, attributed to new physician and hospital customers and a favorable test mix [2] - Physician Lab Services reported strong growth due to market expansion and new customer acquisitions, alongside significant volume and revenue growth from Medicare Advantage plans [3] Advanced Diagnostics Services - Quest Diagnostics' Advanced Diagnostics services, including molecular genomics and oncology tests, have shown strong growth, particularly in brain health, women's health, and advanced cardiometabolic health in Q2 2024 [4] - The Alzheimer's disease portfolio, including AD-Detect blood testing and cerebrospinal fluid tests, is a key growth driver, with plans to expand the biomarker offerings [5] Financial Performance - The stock has appreciated by 18.8% over the past six months, outperforming the industry average of 11.9%, with expectations for continued upward movement due to core business expansion strategies [7] Challenges Faced - The transition away from COVID-19 testing has led to a significant revenue decline of nearly 85% in 2023, with a projected $175 million decrease in COVID-19 revenues for 2024 [8] - Concerns regarding solvency are present, with long-term debt at $3.82 billion and cash reserves of only $271 million, leading to a declining times interest ratio of 7.7% [9]